(Reuters) - BioVeris said through the acquisition, Roche will own the complete patent estate of the electrochemiluminescence technology deployed in its Elecsys product line.
Roche Diagnostics will be able to expand its immunochemistry business from the human diagnostics field into new market segments, BioVeris said in a statement.
Read more at Reuters.com Mergers News
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment